摘要
目的:观察噻托溴铵与布地奈德/福莫特罗联合吸入和噻托溴铵单独吸入对慢性阻塞性肺疾病(COPD)患者的疗效及安全性。方法:58例COPD患者随机分为2组:治疗组30例,给予噻托溴铵(18μg,1次/d)联合布地奈德/福莫特罗(160/4.5μg,2次/d)吸入治疗;对照组28例,给予噻托溴铵(18μg,1次/d)吸入治疗。观察患者治疗前、治疗8周和16周后肺功能及临床症状的变化。结果:治疗8周和16周后,2组FEV1和SGRQ症状评分均较治疗前明显改善(P<0.05),治疗组FEV1和SGRQ症状评分的改善显著高于对照组(P<0.05);治疗组白天使用沙丁胺醇次数更少(P<0.05)。各组均未出现明显不良反应。结论:噻托溴铵与布地奈德/福莫特罗联合吸入治疗COPD,疗效优于噻托溴铵单药治疗。
Objective：To compare combination treatment with tiotropium plus budesonide/formoterol versus treatment with tiotropium alone in patients with chronic obstructive pulmonary diseases（COPD） . Methods：58 subjects with diagnosed COPD were randomly divided into treatment group（n=30） and control group（n=28） . Treatment group was treated with tiotropium（18μg,once-daily） plus budesonide/formoterol（160/4.5μg,twice-daily） ,control group was treated with tiotropium（18μg,once-daily） .The symptoms and lung function was observed before and after treatment of 8 weeks and 16 weeks. Results：Significantly greater improvements from baseline in the FEV1 and SGRQ symptom scores were seen in two groups at all time points（p0.05） . Compared with control group,significantly greater improvements in the FEV1 and SGRQ symptom scores were seen in treatment group at all time points（p0.05） . Patients in treatment group had less need for daytime albuterol use（p0.05） . Both treatments were well tolerated. Conclusions：This study demonstrated that combination treatment with tiotropium plus budesonide/formoterol results in greater therapeutic benefits than tiotropium alone.
出处
《现代生物医学进展》
CAS
2010年第2期302-304,共3页
Progress in Modern Biomedicine
